01 August 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of Catherine Isted, ACMA, as Chief Executive Officer (“CEO”), effective 1 September 2022.
Strategic shift to fully focus on ReNeuron’s Proprietary Exosomes Platform
04 July 2022: ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies, announces its preliminary results for the year ended 31 March 2022.
ReNeuron has negotiated a Supplemental Terms Agreement with potential to generate revenue of up to £6m
01 July 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, is pleased to announce that it has negotiated and signed a Supplemental Terms Agreement with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”; stock code: 600196. SH, 02196. HK) which has the potential to generate revenues of up to £6m for the Company.
20 June 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, will announce its preliminary results for the year ended 31 March 2022 on Monday 4 July 2022.
3 May 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that the Company will be attending the International Society of Cell and Gene Therapy Annual Meeting (ISCT 2022) from the 4-7 May in San Francisco, California.
22 March 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Dr Tim Corn and Mark Evans have resigned as Non-Executive Directors of the Company and that Martin Walton has been appointed as a Non-Executive Director, all with immediate effect.
22 March 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces the appointment of Liberum Capital Limited as the Company’s Nominated Adviser and Joint Broker with immediate effect.
11 February 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces that Olav Hellebø is standing down as CEO and executive director of the Company and will leave the Company on 28 February 2022.
28 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell based Exosome Technologies, announces that it will provide a live presentation and Q&A for investors on Friday 4 February 2022 at 12.00pm (GMT).
Priority focus now on Exosome drug delivery technology & Partnerships Ophthalmology assets to be out-licensed
18 January 2022: ReNeuron Group plc (AIM: RENE), a UK-based leader in Stem Cell and Exosomes Technologies, announces a strategic update following a review of the latest data from the hRPC (human retinal progenitor cells) Phase 2a clinical trial for retinitis pigmentosa (RP) and an assessment of the commercial potential for its Exosome technology.
